Unadjusted outcomes: RR from logistic regression
| (1) | (2) | (3) | (4) | (5) | (6) | |
| Month 4 combined prevalence of four STIs tested by NAAT* | Month 8 combined prevalence of four STIs tested by NAAT* | Month 12 combined prevalence of four STIs tested by NAAT* | Month 12 combined measure for three STIs detected by serology at baseline and month 12† | Month 12 combined prevalence of four STIs tested by NAAT* men only | Month 12 combined prevalence of four STIs tested by NAAT* women only | |
| High-value CCT (95% CI) | 1.06 (0.74 to 1.38) | 0.86 (0.60 to 1.12) | 0.80 (0.54 to 1.06) | 1.09 (0.76 to 1.43) | 0.70 (0.34 to 1.07) | 0.85 (0.55 to 1.15) |
| Low-value CCT (95% CI) | 0.97 (0.66 to 1.28) | 0.80 (0.55 to 1.04) | 1.05 (0.75 to 1.35) | 1.03 (0.71 to 1.35) | 1.25 (0.73 to 1.77) | 0.94 (0.62 to 1.25) |
| Number positive | 246 (11.7%) | 260 (12.3%) | 262 (11.7%) | 232 (10.4%) | 99 (9.0%) | 163 (14.3%) |
| N | 2105 | 2117 | 2242 | 2241 | 1105 | 1137 |
| Number positives by study arm | ||||||
| Control arm | 112 (11.6%) | 133 (13.5%) | 126 (12.1%) | 104 (10.0%) | 47 (9.0%) | 79 (15.2%) |
| High-value CCT | 70 (12.3%) | 66 (11.6%) | 57 (9.7%) | 64 (11.0%) | 18 (6.4%) | 39 (12.9%) |
| Low-value CCT | 64 (11.3%) | 61 (10.8%) | 79 (12.8%) | 64 (10.4%) | 34 (11.3%) | 45 (14.2%) |
Robust SEs in parentheses, clustered at both the household and the subvillage levels.
The reference group for the computation of the RRs is the control group.
↵* Chlamydia, gonorrhoea, trichomonas, Mycoplasma genitalium.
↵† HIV, herpes simplex virus 2, syphilis.
CCT, conditional cash transfer; NAAT, nucleic acid amplification test; STI, sexually transmitted infection.